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Despite its widespread use in North America and many other parts of the world, the safety of etomidate 
as an induction agent for rapid sequence intubation in septic patients is still debated. In this article, 
we evaluate the current literature on etomidate, review its clinical history, and discuss the controversy 
regarding its use, especially in sepsis. We address eight questions: (i) When did concern over the 
safety of etomidate first arise? (ii) What is the mechanism by which etomidate is thought to affect the 
adrenal axis? (iii) How has adrenal insufficiency in relation to etomidate use been defined or identified 
in the literature? (iv) What is the evidence that single dose etomidate is associated with subsequent 
adrenal-cortisol dysfunction? (v) What is the clinical significance of adrenal insufficiency or dysfunction 
associated with single dose etomidate, and where are the data that support or refute the contention that 
single-dose etomidate is associated with increased mortality or important post emergency department 
(ED) clinical outcomes? (vi) How should etomidate’s effects in septic patients best be measured? (vii) 
What are alternative induction agents and what are the advantages and disadvantages of these agents 
relative to etomidate? (viii) What future work is needed to further clarify the characteristics of etomidate 
as it is currently used in patients with sepsis? We conclude that the observational nature of almost all 
available data suggesting adverse outcomes from etomidate does not support abandoning its use for 
rapid sequence induction. However, because we see a need to balance theoretical harms and benefits 
in the presence of data supporting the non-inferiority of alternative agents without similar theoretical risks 
associated with them, we suggest that the burden of proof to support continued widespread use may 
rest with the proponents of etomidate. We further suggest that practitioners become familiar with the use 
of more than one agent while awaiting further definitive data. 
[West J Emerg Med. 2010; 11(2):161-172.]
When did concern over the safety of etomidate first arise?
Etomidate was first introduced into clinical practice in 
Europe in 1972 and was approved for use in the United States 
in 1983. In early June 1983, and later that same month, letters 
to the editor were published in The Lancet describing increased 
mortality in the setting of continuous sedation for trauma 
patients after the introduction of etomidate.1,2
In these reports Ledingham and Watt, in Glasgow, noticed 
that prior to etomidate introduction patient mortality ranged 
from 22-29%, whereas after etomidate introduction, mortality 
rose to 44%, despite no significant changes in the injury severity 
score (ISS) throughout the study period. Comparing patient 
outcomes from 1979 through 1980 (a total of 55 patients; mean 
age 55 years; ISS 24) with outcomes during 1981 through 1982 
(a total of 88 patients; mean age 35 years; ISS 26), they found 
that despite the lower mean age of the latter group and a similar 
ISS, mortality increased from 25% when sedation agents were 
primarily morphine and benzodiazepines to 44% when sedation 
agents were primarily morphine and etomidate. Three quarters 
of the patients in each group were mechanically ventilated, and 
it was in these patients that the increased mortality appeared 
to occur. When patients in each group were stratified strictly 
by sedation agent, the results were even more striking. For all 
patients, mortality was 25% in patients not receiving etomidate 
and 69% in patients who received etomidate. When stratified 
by severity of illness using the ISS, the differences in mortality 
were as follows: ISS 10-20: 6% versus 50%; ISS 21-30: 36% 
versus 77%; and ISS greater than 30: 35% versus 100%. The Volume XI, no. 2  :  May 2010             162  Western Journal of Emergency Medicine
authors noted that suppression of adrenocortical function, which 
had recently been reported in rats3 and critically ill patients,4, 
5 might explain the apparent effect of etomidate. A footnote 
by the editor accompanying this report notes: “the company 
(Janssen) has agreed to cease promotion of the drug for sedation 
in intensive care.”
In a follow-up letter in late June 1983, the same group 
reported that their initial findings led to the end of etomidate 
use at their institution.1 Following this decision, they noted that 
21 patients were treated with an alternative sedative agent, 15 
of whom were regarded as critically ill, and none were found 
to have low cortisol levels. In a 1984 study, they reported that 
mortality fell to 25% in 12 patients treated after etomidate use 
was discontinued.6
Criticisms of these reports began almost immediately. In 
The Lancet of June 25, 1983, a letter responding to Ledingham 
and Watt’s initial report notes “alarm that a technique so useful 
in critically ill patients can so easily be discredited by a letter 
so lacking in objective information,” and suggests the effect 
of a number of additional confounding variables. Another 
letter suggests that the greater depth of anesthesia obtained 
with etomidate may explain the mortality. Additional reports 
by Fellows et al.7 in late 1983 as well as by Chee et al.8 and by 
Logan and McKee9 in early 1984, all in the British Medical 
Journal, lent further support to the relation between etomidate 
and the suppression of adrenal steroidogenesis. 
Several recent articles and letters to the editor in various 
journals question the safety of etomidate for even a single 
bolus dose in patients with illnesses such as sepsis or trauma 
that rely upon an adrenal stress response,10-18 citing the risk 
of causing relative adrenocortical insufficiency after a single 
bolus. Jackson, in March 2005,12 discusses a number of 
small randomized studies reporting significant but transient 
adrenocortical suppression after etomidate administration, and 
notes that these studies failed to prove that the resultant adrenal 
dysfunction was insignificant. In an editorial accompanying 
Jackson’s article,19 the effect of short-term suppression of 
adrenal synthesis on patient outcomes is described as being 
unclear, with the authors noting that etomidate is still a useful 
agent for the induction of unconsciousness, and when combined 
with muscle relaxation provides the best scenario for rapid, 
smooth, hemodynamically stable intubation.19 Zed et al.18 
conclude that given the significant evidence that etomidate 
causes transient adrenal insufficiency of uncertain clinical 
effect, further research is necessary. Bloomfield and Noble11 
suggest that a moratorium on the use of etomidate in critically 
ill patients outside clinical trials may be prudent until its safety 
is established. In contrast, Crozier20 suggests that “the fervor 
of the current discussion is excessive, particularly since it is 
based on rather shaky and perhaps misinterpreted data,” and 
notes that although the case against etomidate might appear 
compelling, none of the studies were actually designed to test 
the effect of etomidate on mortality. Morris and McAllister16 
question whether etomidate’s reputation for being safe in 
emergency anesthesia is justified and ask if it should continue 
to be used in any practice. Schultz-Stubner,17 in a letter to the 
editor responding to Vincent and Berre,21 cites recent evidence13 
for a single bolus of etomidate in intensive care patients being 
a major risk factor for the development of relative adrenal 
insufficiency for at least 24 hours. The author suggests that 
etomidate should be avoided and replaced by an amnestic 
dose of a benzodiazepine in combination with an opioid or 
ketamine to facilitate endotracheal intubation in patients with 
traumatic brain injury. Berre and Vincent counter with the fact 
that the decrease in steroidogenesis caused by intravenous 
administration of a single dose of etomidate has never been 
demonstrated to be deleterious and that the advantages of 
etomidate over other agents are numerous. 
In summary: Etomidate was determined to be unsafe for 
long-term use in the ICU shortly after it was introduced in 
the U.S. in 1982. The question of whether a single bolus dose 
of etomidate for rapid sequence induction is safe remains a 
contentious and unresolved issue.
What is the mechanism by which etomidate is thought to 
affect the adrenal axis?
The mechanism of etomidate’s effects on the adrenal axis 
is through a reversible and concentration-dependent blockade 
of 11β-hydroxylase and, to a lesser extent, 11β/18-hydroxylase 
(aldosterone synthase, CYP11B2) and the cholesterol side-
chain cleavage enzyme known as cholesterol desmolase, or 
P450scc. Early characterization of the mechanism was reported 
in May 1984 by Wagner et al.,22 who described the effect of 
etomidate infusion on cortisol, and the aldosterone responses 
to stimulation with adrenocorticotropic hormone (ACTH), in 
five patients. Wagner et al. also examined the direct effects of 
etomidate on enzymes in rat cells, noting a marked suppression 
of adrenal steroidogenesis followed by gradual recovery of 
glucocorticoid production during four days of observation after 
stopping etomidate infusion. They concluded by recommending 
that physicians consider treating selected patients with 
corticosteroids if etomidate is used for induction. Decreased 
cortisol and aldosterone levels due to this adrenal suppression 
have been documented to occur approximately 30 minutes after 
a single induction dose of etomidate, with the duration of the 
effect being as long as 24 hours to 48 hours.13,15,23-26
In summary: The mechanism of etomidate’s affect on the 
adrenal axis is well characterized and uncontroversial.
How has adrenal insufficiency in relation to etomidate use 
been defined or identified in the literature? 
No gold standard exists for the diagnosis of relative adrenal 
insufficiency. The methods currently used include measuring 
cortisol concentrations, cosyntropin stimulation testing, and 
determining various ratios of cortisol, 11-deoxycortisol, 
ACTH, and other hormone intermediates and derivatives. 
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The cosyntropin test involves measurement of baseline serum 
cortisol, then the parenteral administration of 250 mcg of 
synthetic ACTH, followed by serum cortisol measurements 
at 30 minutes and 60 minutes later. The normal response 
is considered an increase of greater than 9 mcg of cortisol 
per deciliter. In an excellent discussion of the assessment 
of adrenocortical function in the critically ill, Rai et al.27 
note that although adrenocortical function is essential for 
patient survival during critical illness, what constitutes 
adrenocortical insufficiency in critically ill patients is not 
clear. Absolute insufficiency, as defined by very low plasma 
cortisol concentrations, is uncommon in the ICU population 
(and moreover, it is difficult to determine what constitutes a 
normal reference range for the critically ill patient). The term 
“relative adrenocortical insufficiency” (abnormal increases in 
plasma cortisol concentrations following an ACTH stimulus) 
is controversial since definitions have been obtained through 
studies in unstressed volunteers. Critics note that the test is only 
a measurement of adrenal reserve, not adrenal function, and 
thus its use to determine adrenal insufficiency in the setting of 
sepsis is inappropriate. A normal response to the test does not 
rule out adrenal suppression, because the dose of ACTH used 
is far higher than normal physiological concentration and may 
override adrenal resistance to corticotropin, thus producing 
a false-negative test in patients with mild secondary adrenal 
insufficiency. An alternative “low-dose” cosyntropin test, using 
1 mcg of corticotrophin, has been suggested. A recent consensus 
statement from the American College of Critical Care Medicine 
(ACCM) suggests that dysfunction of the hypothalamic-
pituitary-adrenal axis in critical illness is best described by 
the term critical illness–related corticosteroid insufficiency 
(CIRCI), and that the terms absolute or relative adrenal 
insufficiency are best avoided in the context of critical illness.28 
Regardless of the debate over how best to test for adrenal 
insufficiency, a clear and unambiguous relation between 
serum cortisol and mortality in critical illness has not been 
demonstrated. Plasma cortisol assays tend to vary considerably 
between different institutions, and circadian rhythms of cortisol 
levels result in significant fluctuations over a 24-hour period, 
such that the diagnosis of impaired cortisol secretion may 
be wrong if based on a single plasma cortisol measurement. 
Commercial assays only measure the total plasma cortisol, 
so physiologically significant increases in free cortisol can be 
missed. For the many reasons noted above, there continues to 
be uncertainty about the optimal method of detecting clinically 
significant adrenal insufficiency in acutely ill patients. This is 
one important factor that makes the relation between etomidate 
and adverse outcome difficult to address.
In summary: Although it is clear that etomidate inhibits 
adrenal hormone production, definitions to uniformly 
characterize levels of adrenal inhibition are still being 
developed.
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Figure 1. Adrenal aldosterone and cortisol biosynthetic pathways. Key steps have been labeled with the enzymes responsible for 
catalysis. Enzymes inhibited by etomidate have been demarcated by the blocked white arrowheads. Etomidate primarily inhibits 
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What is the evidence that single dose etomidate is associated 
with subsequent adrenal-cortisol dysfunction?
Multiple studies have evaluated the effect of etomidate 
on adrenocortical function in patients undergoing elective 
operative procedures, with the results showing evidence of 
adrenocortical dysfunction after a single induction dose. In a 
small observational study of patients undergoing minor surgery, 
Duthie et al.29 compared the use of etomidate to thiopentone 
by measuring the effect on synthesis of corticosteroid 
hormones and ACTH, and found higher levels of plasma 
11-deoxycorticosterone (an intermediate molecule in steroid 
synthesis) at four hours and at 24 hours after administration in 
patients receiving etomidate. However, the clinical significance 
of the results remains uncertain in this small study performed in 
non-septic patients.
In 2001, Schenarts et al.26 performed a prospective 
randomized controlled (but non-blinded) trial of a small 
number of consecutive patients presenting to the ED requiring 
intubation. These patients were randomized to receive a 
single bolus dose of either midazolam or etomidate during a 
standardized rapid sequence intubation with succinylcholine. 
The primary outcome variable was adrenocortical function 
at 4, 12, and 24 hours post induction, as measured by serum 
cortisol responses to cosyntropin testing. After exclusion of 
13 patients, eight control patients and 10 patients were given 
etomidate; all controls had a normal response to cosyntropin at 
four hours, whereas only 30% of the etomidate patients had a 
normal response. Patients were excluded if steroids were used 
at any time during the first 24 hours of hospitalization. Although 
responses to the cosyntropin testing were blunted, baseline 
cortisol levels, although lower than in controls, tended to be 
within normal laboratory reference ranges. Normal responses 
returned at 12 to 24 hours post induction. Although no 
differences in clinical outcomes were reported, it is interesting 
to note that for the patients receiving etomidate, the number 
of hours intubated and the time in ICU were roughly twice the 
times recorded for the patients receiving midazolam. Also, the 
hospital length of stay (LOS) was an average two days longer 
for the etomidate group.
In a retrospective study of patients with septic shock, 
Mohammad et al.15 examined the incidence of relative adrenal 
insufficiency after etomidate administration. After identifying 
1,207 consecutive patients who had their serum cortisol 
concentrations measured, these authors were able to include 
in their study 152 adults with septic shock who underwent 
cosyntropin stimulation testing; 38 of these patients received 
etomidate, with an incidence of relative adrenal insufficiency 
of 76% compared to 51% in the controls (p = 0.0077). 
Relative adrenal insufficiency was defined as a rise in serum 
cortisol of less than 9 mcg per deciliter. Patients who did not 
authorize their medical records to be reviewed for research 
were excluded; however, this number is not readily available in 
the published paper. Overall hospital mortality rate was 57%, 
with etomidate patients having a mortality of 63% and controls 
having a non-significantly different mortality of 55% (p = 0.45).
 In 2008, den Brinker et al.23 reported a retrospective 
analysis of 60 pediatric patients who presented with 
meningococcal sepsis between 1997 and 2004. Of these 
patients, 23 had been intubated with etomidate, eight without 
etomidate, and 29 had not been intubated. Children receiving 
etomidate had significantly lower cortisol levels and retained 
decreased ratios of cortisol to 11-deoxycortisol up to 24 hours 
after admission. However, severity of illness was not specified 
in this population. Patients given etomidate also had higher 
mortality rates (although the clinical outcome is not emphasized 
in the manuscript, given the limitations in attributing causation 
through this retrospective study). The authors hypothesize that 
etomidate “might therefore increase risk of death.”
Vinclair et al.30 performed a prospective observational 
study of 40 ICU patients without sepsis who received etomidate 
for endotracheal intubation. The patients were assessed using 
serial cosyntropin tests and measurements of 11-deoxycortisol 
levels at 12, 24, 48, and 72 hours after etomidate administration. 
Adrenal inhibition was defined as a rise of less than 9 mcg 
per deciliter after ACTH stimulation and an accumulation of 
11-deoxycortisol of greater than 8 nmol per liter from baseline. 
On the basis of this definition, etomidate-related adrenal 
insufficiency occurred in 80% of the patients at 12 hours, 46% 
at 24 hours, 9% at 48 hours, and 7% at 72 hours.
In summary: Data from these studies support the contention 
that a single bolus dose of etomidate results in adrenal-cortisol 
dysfunction as measured by laboratory analysis.
What is the clinical significance of adrenal insufficiency or 
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Figure 2. Standard-dose short cosyntropin stimulation test. Cortisol 
response is measured as the difference between the baseline 
cortisol level and the highest of the concentrations taken after 
cosyntropin administration. Relative adrenal insufficiency is typically 
defined by a response of <9 μg/dL.
T‐1 min: Baseline cortisol drawn
T0: 250 μg cosyntropin given IV
T30 min: Repeat cortisol level drawn
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dysfunction associated with single-dose etomidate? Where 
are the data that support or refute the contention that 
single-dose etomidate is associated with increased mortality 
or important post-ED clinical outcomes?
The CORTICUS trial reported in 2008 by Sprung et 
al.31 provided evidence of the clinical significance of adrenal 
insufficiency associated with single-dose etomidate. This 
study evaluated the effect of randomized steroid use on the 
outcomes of septic patients, but did not randomize the use 
of sedative agents. Of 499 patients randomized to receive 
either hydrocortisone or placebo, there was no statistically 
significant difference in mortality (39.2% versus 36.1% in the 
placebo group) at 28 days for patients who did not respond to 
corticotropin stimulation testing or for patients who did have a 
response to corticotropin (28.8% versus 28.7% in the placebo 
group). When all groups were combined, 86 of 251 patients 
in the hydrocortisone group versus 78 of 248 patients in the 
placebo group had died at 28 days (34.3% versus 31.5%). The 
authors noted more episodes of superinfection, including new 
sepsis and septic shock, in patients treated with steroids. A post-
hoc analysis to evaluate the association between outcomes and 
the use of etomidate showed that mortality at 28 days increased 
among patients who received etomidate before randomization 
(mortality was 45.1% in the hydrocortisone group and 40.0% 
in the placebo group). Mortality in patients who did not receive 
etomidate was 31.5% in the hydrocortisone group and 29.6% in 
the placebo group. This difference was statistically significant, 
with p = 0.03. In view of the lack of randomization of these 
patients to receive etomidate or alternative agents, and the 
consequent limitation in causative attribution, the authors state 
that “an association between etomidate and the likelihood of 
adrenal hypo-responsiveness was also found in our study.” 
In 2002, Annane et al.32 reported a reduction in mortality 
after low-dose corticosteroid administration in septic shock 
patients who failed cosyntropin testing. Almost two years into 
the study, these investigators amended the eligibility criteria to 
exclude patients who had received etomidate for endotracheal 
intubation. Of 72 patients who had received a single dose of 
etomidate to that point, 68 (94.4%) failed their cosyntropin 
test, compared to 71% of those who did not receive etomidate. 
A subgroup analysis of these 68 non-responders revealed 
significantly higher mortality rates in those who had been 
randomized to receive placebo versus corticosteroids (75.7% 
versus 54.8%, respectively; p = .03).
A prospective observational study by Malerba et al.13 also 
indirectly suggests a statistically significant increase in mortality 
due to etomidate-associated relative adrenal insufficiency. In 
this study of 62 patients needing mechanical ventilation for 
greater than 24 hours, each patient’s cosyntropin response was 
tested at 24 hours after endotracheal intubation. Multivariate 
analysis revealed that etomidate was associated with relative 
adrenal insufficiency (OR 12.21; 95% CI 2.99–49.74) and that 
the patients with relative adrenal insufficiency demonstrated 
more organ dysfunction and higher mortality (70.4% versus 
31.4%, p < 0.005).
Lipiner-Friedman et al.33 describe data collected from 
patients in 20 European ICUs. Data for 77% of the patients 
were extracted from databases of previously published studies, 
with data for the remaining patients coming from centers 
participating in (but prior to the actual start of) the CORTICUS 
study. After evaluation of 562 patients, 477 were retained (due 
to various exclusionary criteria). Of these patients, 237 received 
etomidate, resulting in an unadjusted odds ratio for death of 
1.53 (95% CI 1.06-2.26), which becomes nonsignificant after 
adjustment for severity of illness in multivariate analysis.
Ray et al.34 conducted a retrospective review of 159 septic 
shock patients and assessed the associations between outcome 
and induction agent, vasopressor use, inotrope use, and steroid 
use. Vasopressor use, inotrope use, or steroid administration 
and outcome were found not to be related to the induction agent 
chosen. The induction agent used and timing of administration 
did not influence subsequent steroid administration or dose of 
hydrocortisone. Of 87 patients who started steroid therapy, 58 
(67%) died; of 60 patients who received no steroid, 36 (60%) 
died. Forty-three patients who received etomidate also received 
steroids; 32 of these patients (74%) died compared with 19 
(58%) who died and did not receive steroids (p = 0.121). 
Hospital mortality was as follows: 69% (etomidate), 56% 
(propofol), 46% (thiopental), 67% (other), and 81% (none), 
with no statistically significant differences found. Vasopressor 
therapy was required less frequently and in smaller doses during 
endotracheal intubation when etomidate was used to induce 
anesthesia. The authors concluded that neither clinical outcome 
nor therapy was affected by the use of etomidate.
In late 2008, Hildreth et al.25 described a prospective and 
randomized (but nonblinded) study of trauma patients requiring 
intubation. Patients were randomized to receive either etomidate 
(0.3 mg per kilogram) or fentanyl (100 mcg) and midazolam 
(5 mg). Although 61 patients met inclusion criteria, 31 were 
subsequently excluded from data analysis for various reasons. 
The average baseline serum cortisol for the etomidate group 
was 31 mcg per deciliter versus 27 mcg per deciliter for the 
controls; after medication administration, the serum cortisol 
average for the etomidate group was 18 versus 28 mcg per 
deciliter, with ACTH stimulation testing resulting in increases 
of 4.2 mcg per deciliter for the etomidate group versus 11.2 mcg 
per deciliter in controls. Hospital LOS for the etomidate group 
was 13.9 days versus 6.4 for the controls; ICU length of stay 
was 8.1 days versus three, and ventilator days were 6.3 days 
versus 1.5 (all comparisons were significant). Mortality between 
groups was not statistically significant, with 16 of 18 patients in 
the etomidate group surviving (11% mortality) and all patients 
in the control group surviving. The large number of excluded 
patients, combined with the small study size, unfortunately 
limits the generalizability of these findings. 
A retrospective analysis of intubated septic patients found 
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a non-statistically significant increase in mortality in patients 
given etomidate.35 Of the 46 patients receiving alternative 
agents or no agent, 18 died, yielding an unadjusted mortality of 
39.1% (95% CI 25.5% to 54.6%), while of the 135 receiving 
etomidate, 63 died, for an unadjusted mortality of 46.7% 
(95% CI 38.1% to 55.4%).35 A prospective observational study 
performed by the same investigators followed the outcomes of 
all patients meeting sepsis criteria intubated over a seven-month 
period.36 A total of 106 patients with sepsis were intubated 
over the study period; 74 received etomidate and 32 received 
alternative agents or no induction agent. In-hospital mortality 
of patients given etomidate (38%, 95% CI 28% to 49%) was 
similar to those receiving alternatives (44%, 95% CI 28% to 
61%). Surviving patients had a non-statistically significant 
increase in hospital median LOS after receiving etomidate (10 
days) compared to those receiving alternatives (7.5 days), p 
= 0.08.36 In these studies, however, the retrospective design 
and lack of randomization of patients limits the possibility of 
establishing causation.
In 2009, Warner et al.37 performed a retrospective analysis 
of data previously collected as part of a clinical trial evaluating 
hypertonic saline (HS) resuscitation in hypotensive blunt 
trauma patients over the age of 18. The primary endpoint was 
development of acute respiratory distress syndrome (ARDS). 
Of the 209 patients initially enrolled in the HS trial, 107 
underwent RSI; 13 died within the first 24 hours and could not 
be assessed for ARDS. There were no statistically significant 
differences in mortality between those that received etomidate 
and those that received benzodiazepines (15% versus 25%, p = 
0.33). Of the 94 patients that underwent RSI and survived 24 
hours, 35 received etomidate and 59 received benzodiazepines 
at the discretion of either the treating physician or EMS 
provider. In univariate analyses, the authors found a statistically 
significant increase in the development of ARDS and Multiple 
Organ Dysfunction Score (MODS) in patients given etomidate. 
In multivariable analysis controlling for HS, Acute Physiology 
and Chronic Health Evaluation (APACHE II) scores, etomidate, 
massive transfusion, and ISS, the authors found that use of 
etomidate, an APACHE II score >20, and massive transfusion 
remained significant predictors of the development of ARDS 
and MODS. Also, in the most severely injured patients with 
APACHE II scores of >20, patients that received etomidate 
had significant increases in hospital LOS, ventilator days, and 
ICU length of stay. Conclusions regarding etomidate use being 
causally related to the development of ARDS and MODS were 
limited because the analysis was post-hoc.
In 2009, Cuthbertson et al.38 reported further details on 
a sub-group of patients in the CORTICUS trial.31 Their goal 
was to evaluate the effects of etomidate on corticotropin 
response and 28-day mortality. Of the 499 patients analyzed, 
96 received etomidate within 72 hours of inclusion in the 
study. Univariate analysis revealed that the number of non-
responders to corticotropin was significantly higher in patients 
who received etomidate than in other patients (61.0%, versus 
44.6%, p = 0.004), and mortality was increased in those who 
received etomidate (OR = 1.70, 95% CI: 1.07–2.68; p = 0.02). 
The authors also performed two logistic regression analyses. In 
the first model they adjusted for the treatment group (steroid/
placebo), response to corticotropin (responder/non-responder), 
baseline cortisol value (as continuous variable), and simplified 
acute physiology score (SAPS II), and found etomidate to have 
a non-statistically significant effect on mortality (p = 0.06). 
The second model further added the sequential organ failure 
assessment (SOFA) score, and revealed a statistically significant 
increase in mortality in patients who received etomidate (OR 
1.75, 95% CI 1.06 to 2.90). In patients receiving etomidate, 
administration of hydrocortisone did not have a significant 
effect on mortality. This study remains limited by the non-
randomized administration of etomidate, and the limitations 
inherent in making adjustments for severity of illness. 
Jabre et al.39 recently performed a multicenter, controlled, 
single-blind trial of all non-pregnant patients over the age 
of 18 who required sedation for emergency rapid sequence 
intubation. Patients were randomized to receive either 0.3 mg/
kg of etomidate or 2 mg/kg of ketamine. The primary outcome 
was the maximum SOFA score during the first three days in the 
ICU. In an effort to capture the most critically ill population, 
patients were excluded from analysis after randomization if they 
died prior to reaching the hospital or were discharged from the 
ICU within three days. Of the 655 patients randomized, 181 
were excluded due to the aforementioned reasons, four due to 
missing data, and one because of withdrawn consent, which left 
234 patients in the etomidate group and 235 in the ketamine 
group. The authors found no significant difference between 
the etomidate and ketamine groups in their maximum SOFA 
scores during the first three days in the ICU (10.3 versus 9.6, p 
= 0.056), and in secondary outcomes, no significant difference 
between the groups in their changes in SOFA scores, 28-day 
mortality, ventilator-free days, transfusion, fluid, or vasopressor 
requirements, Glasgow outcome score, or ICU-free days. Ease 
of intubation was also similar in the two groups, probably as a 
result of the muscle relaxant effect provided by succinylcholine, 
which was administered to all intubated patients. The only 
statistically significant difference between the groups was a 
decrease in adrenal responsiveness in patients given etomidate. 
Sub-group analysis of septic patients showed a non-statistically 
significant 7.2% increased risk of death in patients given 
etomidate (OR 1.4, 95% CI 0.5 to 3.5). However, the small 
total number of septic patients (41 receiving etomidate and 35 
receiving ketamine) limits the power of this analysis. 
In summary: The studies that support the contention that 
single-dose etomidate is associated with increased mortality 
or important adverse post-ED clinical outcomes are limited by 
their observational design. Thus, the strength of any association 
between etomidate and an adverse outcome can imply, but not 
prove, causation.
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How should etomidate effects in septic patients best be 
measured? 
The optimal method of determining relative adrenal 
insufficiency in critically ill patients continues to be a matter 
of debate. Various methods have been suggested, including a 
randomly drawn cortisol level of less than 15 mcg per deciliter, 
combined with an increment in cortisol level after a cosyntropin 
test of less than 9 mcg per deciliter; a cortisol increment after 
a cosyntropin test of less than 9 mcg per deciliter regardless of 
basal cortisol levels; and a random cortisol level of less than 25 
mcg per deciliter in hypotensive patients or less than 20 mcg 
per deciliter in normotensive patients.
Rai et al.27 recommend the use of plasma-free cortisol 
in the assessment of adrenal function in critical illness 
and further suggest that the low-dose corticotropin test 
is more sensitive than the conventional high-dose test. 
Cortisol is bound to an alpha-globulin called transcortin, 
or corticosteroid-binding globulin, as well as albumin, and 
also exists in a free form. The free hormone is the active 
form, and less than 5% exists as free cortisol in the plasma 
at normal levels of total plasma cortisol. During critical 
illness, levels of cortisol-binding globulin decrease, and free 
cortisol levels may increase secondary to the cleavage of 
cortisol-binding globulin by neutrophil elastase. However, 
because commercial assays only measure the total plasma 
cortisol, a physiologically significant increase in free cortisol 
can be missed. Serum total cortisol levels can be reduced in 
hypoproteinemic patients, while serum-free cortisol levels are 
elevated. Rai et al.27 suggest that baseline free cortisol levels 
of 2 mcg per deciliter should be considered the threshold level 
that identifies patients at risk for adrenal insufficiency during 
critical illness, and that a corticotropin stimulated serum-
free cortisol concentration of 3.1 mcg per deciliter or greater 
defines a normal response in critically ill patients.
According to a recently published ACCM consensus 
statement,28 CIRCI is best diagnosed (after administration of 
250 mcg of cosyntropin) by a delta cortisol of <9 mcg/dL or 
a random total cortisol of <10 mcg/dL. Measurement of free 
cortisol is not recommended for routine use, because although 
the free cortisol assay has some advantage over the total 
serum cortisol, this test is not readily available. Furthermore, 
the normal range of free cortisol in critically ill patients is 
currently unclear.28 With regard to the use of supplemental 
steroids, the consensus is that clinical criteria, as opposed 
to ACTH stimulation testing, should be used to identify 
which patients with septic shock or ARDS should receive 
glucocorticoids.28
In summary: Although the clinical significance of 
adrenocortical suppression caused by etomidate remains 
uncertain, measurments of delta cortisol after administration 
of 250 mcg of cosyntropin, or measurement of a random 
cortisol level, appear reasonable to identify critical illness 
related corticosteroid insufficiency (CIRCI).
What are alternative induction agents? What are the 
advantages and disadvantages of these agents relative to 
etomidate?
Both ketamine and benzodiazepines, particularly midazolam, 
appear to be suitable alternatives to etomidate for most cases of 
rapid sequence intubation of septic patients. The recommended 
dose of midazolam for induction is between 0.1 and 0.3 mg/
kg (although the package insert notes initial dose requirements 
of up to 0.35 mg/kg with resistant cases requiring up to 0.6 mg/
kg). The recommended dosage for diazepam is 0.2-0.5 mg/
kg, methohexital 1.0-3.0 mg/kg, and thiopental 3.0-5.0 mg/
kg. As noted by Sagarin et al.,40 in their review of the National 
Emergency Airway Registry database, under-dosing with 
midazolam is common, despite its minimal hypotensive effects, 
even at high doses used on patients with limited cardiac reserve.
The possibility has been raised that alternative agents, 
such as midazolam, may have increased hypotensive effects 
compared to etomidate.41 However, the literature that suggests 
such adverse outcomes is itself limited by observational 
analyses that suggest associations but cannot prove causality.42-47 
Despite any adjustments made to account for severity of illness, 
the fact remains that unmeasured confounders in these studies 
are likely to have influenced outcome. 
Ketamine has been suggested to have an excellent 
hemodynamic profile, making it a reasonable alternative to 
etomidate, at least in some patients.41 Evidence supporting 
the safety of ketamine for rapid sequence intubation is now 
available in the form of a multicenter randomized controlled 
trial (discussed earlier), which concluded that ketamine is a 
safe and valuable alternative to etomidate.39 Nevertheless, 
prior evidence suggesting adverse cardiovascular effects from 
ketamine may leave some physicians hesitant to adopt it as a 
substitute for etomidate in all patients, particularly in patients 
with known or suspected cardiovascular disease.48,49,50,51 
Additionally, ketamine has historically been avoided by 
clinicians following actual or potential brain injury due to its 
potential to elevate intracranial pressure, despite recent reviews 
questioning the significance of this effect on outcome.52
In summary: Both midazolam and ketamine appear to 
be suitable alternatives to etomidate. Given the limitations in 
available evidence, a strong recommendation for any particular 
agent at this time is not possible; however, with the need to 
balance theoretical harms and benefits in the presence of data 
supporting the non-inferiority of alternative agents which do 
not have similar theoretical risks associated with them, we 
suggest that further studies to support continued widespread use 
of etomidate in sepsis are warranted. As with any therapeutic 
decision, practitioners must choose between agents. There is 
sufficient reason to think that ketamine and midazolam are safe 
alternatives and that in the context of clear sepsis or septic 
shock, these agents should be considered. Practitioners would 
be well served by becoming familiar with the use of more than 
one agent while awaiting further definitive data.
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What future work is needed to further clarify the 
characteristics of etomidate as it is currently used in 
patients with sepsis?
It is possible, or even likely, that the largest randomized 
study to date of etomidate was underpowered for detection of 
mortality differences in septic patients, and that further study 
is warranted.39 Some doubt remains over the safety of using 
etomidate as an induction agent for rapid sequence intubation 
in septic patients.10-12,14-20,23,35,53-57 If etomidate does in fact have a 
negative influence on patient outcome, this will only be proved 
by conducting randomized, controlled studies with sufficient 
power to detect what may be small but clinically important 
differences in outcomes. Such studies will undoubtedly require 
large, multicenter trials. A recent manuscript describes the 
creation of a prioritized Emergency Medical Services for 
Children research agenda specific for multicenter research, 
and concludes that the creation of the Pediatric Emergency 
Care Applied Research Network (PECARN) provides a means 
to answer important clinical controversies, mainly because it 
will facilitate the procedures necessary for conducting large-
scale randomized, controlled trials and observational studies.58 
Likewise, the formation of the Resuscitation Outcomes 
Consortium now provides for a well-developed infrastructure 
for the conduct of multicenter trials, and offers great promise 
for the resuscitation community.59
Because the patient population requiring emergent 
intubation precludes their informed consent being obtained 
prior to treatment, studies of etomidate in these patients 
require exception from informed consent. Historically, this has 
been a challenging proposition, but recent recommendations 
for implementation of community consultation and public 
disclosure under the Food and Drug Administration’s 
“Exception From Informed Consent Requirements For 
Emergency Research” now provides guidance that will 
probably increase the ability of investigators to obtain IRB 
approval to pursue research on etomidate.60 A study in the 
United States (ClinicalTrials.gov Identifier NCT00441792) is 
in its final stages, and the results of this study may shed further 
light on the effects of etomidate. 
CONCLUSION
The observational nature of almost all available data 
suggesting adverse outcomes from etomidate does not currently 
support abandoning its use for rapid sequence induction. On 
the other hand, given the limitations in the available evidence, 
strong support for any particular agent at this point cannot 
reasonably be made. The only published randomized, controlled 
trial evaluating etomidate (comparing it to ketamine) did 
not show a statistically significant difference in outcomes. 
However, the possibility exists that this trial was underpowered 
for the subgroup of patients with sepsis. Because etomidate 
decreases the cortisol response, and because cortisol production 
in some settings may be clinically important, practitioners 
should be familiar with the available evidence while awaiting 
newer studies that may clarify these issues. The authors do not 
currently have unanimous agreement on a single best agent 
but feel that the potential for adverse effects of etomidate in 
clearly septic patients without cardiovascular disease warrants 
consideration of ketamine or midazolam in these patients. 
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Authors Year Design Population
Number of 
patients
Etomidate Dose Outcome Author’s Findings
Duthie DJR, Fraser R, Nimmo 
WS
1985
Prospective, randomized, 
controlled trial
Patients undergoing minor surgery 12 0.3 mg/kg  Plasma steroid levels
Increased 11-deoxycorticosterone in 
patients receiving etomidate
Malerba G, Romano-Girard F, 
Cravoisy A, et al.
2005 Prospective observational Mechanically ventilated ICU patients 62 0.2–0.4 mg/kg
Cortisol level after CST after 24 
hrs of ventilation
Lower cortisol levels in patients given 
etomidate (OR 12.2)
Schenarts CL, Burton JH, Riker 
RR
2001
Prospective, randomized, 
controlled trial
Consecutive patients presenting to the 
ED requiring intubation
31 (13 excluded) 0.3 mg/kg 
Cortisol level after CST at 4, 12, 
and 24 hours post-induction
Decreased cortisol response at 4 hrs 
after etomidate
Mohammad Z, Afessa B, 
Finkielman JD.
2006 Retrospective study Adults with septic shock given a CST 152 Not specified Serum cortisol after CST
Lower cortisol levels in patients given 
etomidate
den Brinker M, Hokken-Koelega 
AC, Hazelzet JA, et al.
2008 Retrospective study Pediatric meningococcal sepsis 60
Median 0.29 mg/kg 
(range 0.20–0.67mg/
kg)
Adrenal hormone concentrations 
after PICU admission and after 
12h and 24h
Children who received etomidate had 
significantly lower cortisol levels
Vinclair M, Broux C, Faure P, et 
al. 
2008
Prospective, observational 
cohort study
Critically ill patients without sepsis who 
received a single dose of etomidate
40
Median 0.33 mg/kg 
(range 0.22 to 0.80 
mg/kg)
Cortisol at baseline and 60 min 
after CST at 12, 24, 48, and 72 
h after etomidate administration
Decreased cortisol response at 12 hrs 
after etomidate, improving by 48 hrs
Sprung CL, Annane D, Keh D, 
et al.
2008
Observational outcome from 
a randomized, double-blind, 
comparison of hydrocortisone 
versus placebo
Patients with septic shock
499 (with subgroup 
of 96 receiving 
etomidate)
Not specified 
(etomidate not 
randomized)
Mortality at 28 days in patients 
not responding to corticotropin 
test
Increased rate of death among 
patients given etomidate (non-
randomized)
Annane D, Sebille V, Charpentier 
C, et al.
2002
Observational outcome from 
a randomized, double-blind, 
comparison of hydrocortisone 
+ fludrocortisone versus 
placebo
Patients with septic shock
300 (with 
subgroup of 72 
patients receiving 
etomidate)
Not specified 
(etomidate not 
randomized)
Mortality at 28 days
Increased rate of death among 
patients given etomidate (non-
randomized)
Malerba G, Romano-Girard F, 
Cravoisy A, et al. 
2005
Prospective observational 
study
Consecutive, acutely ill patients needing 
mechanical ventilation for more than 24 h
62 0.2–0.4 mg/kg 
Response to short corticotropin 
test 
Increased relative adrenocortical 
deficiency seen in patients given 
etomidate
Lipiner-Friedman D, Sprung CL, 
Laterre PF, et al. 
2007 Retrospective cohort study
Patients with severe sepsis and septic shock 
who had undergone an ACTH stimulation 
test on the day of the onset of severe sepsis
477 (237 receiving 
non-randomized 
etomidate)
Not specified 
(etomidate not 
randomized)
In-hospital mortality
Increased mortality (unadjusted) in 
patients receiving etomidate
Ray DC and McKeown DW 2007 Retrospective cohort study Patients with septic shock 159
Median of 12 mg (range 
of 5 mg to 20 mg)
In-hospital mortality No statistically significant differences found
Hildreth AN, Mejia VA, Maxwell 
RA, et al. 
2008
Prospective, randomized, 
controlled, non-blinded study
Adult trauma patients requiring 
intubation
30 0.3 mg/kg 
Adrenal function, length of stay 
on ventilator, ICU, and hospital, 
and in-hospital mortality
Increased adrenal insufficiency, length 
of stay on ventilator, in ICU, and in 
hospital in patients receiving etomidate
Tekwani K, Watts H, Chan C, et 
al.
2008 Retrospective cohort study Intubated patients with sepsis 181
Not specified 
(physician-chosen, 
single dose)
In-hospital mortality No statistically significant differences 
found
Tekwani KL, Watts HF, Rzechula 
KH, et al. 
2009
Non-randomized, prospective 
observational study
Intubated patients with sepsis 106
Not specified 
(physician-chosen, 
single dose)
In-hospital mortality and length 
of stay
No statistically significant differences 
found
Jabre P, Combes X, Lapostolle 
F, et al.
2009
Randomized, controlled, 
single-blind trial
Patients 18 years or older who needed 
sedation for emergency intubation
655 0.3 mg/kg  SOFA score
No statistically significant differences 
found
Cuthbertson BH, Sprung CL, 
Annane D, et al. 
2009
Substudy of CORTICUS 
randomized, double-blind, 
placebo-controlled trial
Patients with septic shock
499 (with subgroup 
of 96 receiving 
etomidate)
Not specified 
(etomidate not 
randomized)
Corticotropin response, 28-day 
mortality
Increased non-responders to 
corticotropin and higher 28-day 
mortality in one multi-variate model in 
patients who were given etomidate
Warner KJ, Cuschieri J, 
Jurkovich GJ, et al. 
2009
Post-hoc analysis of clinical 
trial of prehospital hypertonic 
saline administration
Critically ill trauma patients requiring 
intubation
94
Not specified 
(etomidate not 
randomized)
Development of posttraumatic 
ARDS
Higher rates of late onset ARDS in 
patients given etomidate
CST, corticotropin stimulation test; ICU, intensive care unit; PICU, pediatric intensive care unit; SOFA, sequential organ failure assessment; ARDS, acute respiratory distress syndrome
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Cortisol level after CST after 24 
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etomidate (OR 12.2)
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Prospective, randomized, 
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Consecutive patients presenting to the 
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31 (13 excluded) 0.3 mg/kg 
Cortisol level after CST at 4, 12, 
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Decreased cortisol response at 4 hrs 
after etomidate
Mohammad Z, Afessa B, 
Finkielman JD.
2006 Retrospective study Adults with septic shock given a CST 152 Not specified Serum cortisol after CST
Lower cortisol levels in patients given 
etomidate
den Brinker M, Hokken-Koelega 
AC, Hazelzet JA, et al.
2008 Retrospective study Pediatric meningococcal sepsis 60
Median 0.29 mg/kg 
(range 0.20–0.67mg/
kg)
Adrenal hormone concentrations 
after PICU admission and after 
12h and 24h
Children who received etomidate had 
significantly lower cortisol levels
Vinclair M, Broux C, Faure P, et 
al. 
2008
Prospective, observational 
cohort study
Critically ill patients without sepsis who 
received a single dose of etomidate
40
Median 0.33 mg/kg 
(range 0.22 to 0.80 
mg/kg)
Cortisol at baseline and 60 min 
after CST at 12, 24, 48, and 72 
h after etomidate administration
Decreased cortisol response at 12 hrs 
after etomidate, improving by 48 hrs
Sprung CL, Annane D, Keh D, 
et al.
2008
Observational outcome from 
a randomized, double-blind, 
comparison of hydrocortisone 
versus placebo
Patients with septic shock
499 (with subgroup 
of 96 receiving 
etomidate)
Not specified 
(etomidate not 
randomized)
Mortality at 28 days in patients 
not responding to corticotropin 
test
Increased rate of death among 
patients given etomidate (non-
randomized)
Annane D, Sebille V, Charpentier 
C, et al.
2002
Observational outcome from 
a randomized, double-blind, 
comparison of hydrocortisone 
+ fludrocortisone versus 
placebo
Patients with septic shock
300 (with 
subgroup of 72 
patients receiving 
etomidate)
Not specified 
(etomidate not 
randomized)
Mortality at 28 days
Increased rate of death among 
patients given etomidate (non-
randomized)
Malerba G, Romano-Girard F, 
Cravoisy A, et al. 
2005
Prospective observational 
study
Consecutive, acutely ill patients needing 
mechanical ventilation for more than 24 h
62 0.2–0.4 mg/kg 
Response to short corticotropin 
test 
Increased relative adrenocortical 
deficiency seen in patients given 
etomidate
Lipiner-Friedman D, Sprung CL, 
Laterre PF, et al. 
2007 Retrospective cohort study
Patients with severe sepsis and septic shock 
who had undergone an ACTH stimulation 
test on the day of the onset of severe sepsis
477 (237 receiving 
non-randomized 
etomidate)
Not specified 
(etomidate not 
randomized)
In-hospital mortality
Increased mortality (unadjusted) in 
patients receiving etomidate
Ray DC and McKeown DW 2007 Retrospective cohort study Patients with septic shock 159
Median of 12 mg (range 
of 5 mg to 20 mg)
In-hospital mortality No statistically significant differences found
Hildreth AN, Mejia VA, Maxwell 
RA, et al. 
2008
Prospective, randomized, 
controlled, non-blinded study
Adult trauma patients requiring 
intubation
30 0.3 mg/kg 
Adrenal function, length of stay 
on ventilator, ICU, and hospital, 
and in-hospital mortality
Increased adrenal insufficiency, length 
of stay on ventilator, in ICU, and in 
hospital in patients receiving etomidate
Tekwani K, Watts H, Chan C, et 
al.
2008 Retrospective cohort study Intubated patients with sepsis 181
Not specified 
(physician-chosen, 
single dose)
In-hospital mortality No statistically significant differences 
found
Tekwani KL, Watts HF, Rzechula 
KH, et al. 
2009
Non-randomized, prospective 
observational study
Intubated patients with sepsis 106
Not specified 
(physician-chosen, 
single dose)
In-hospital mortality and length 
of stay
No statistically significant differences 
found
Jabre P, Combes X, Lapostolle 
F, et al.
2009
Randomized, controlled, 
single-blind trial
Patients 18 years or older who needed 
sedation for emergency intubation
655 0.3 mg/kg  SOFA score
No statistically significant differences 
found
Cuthbertson BH, Sprung CL, 
Annane D, et al. 
2009
Substudy of CORTICUS 
randomized, double-blind, 
placebo-controlled trial
Patients with septic shock
499 (with subgroup 
of 96 receiving 
etomidate)
Not specified 
(etomidate not 
randomized)
Corticotropin response, 28-day 
mortality
Increased non-responders to 
corticotropin and higher 28-day 
mortality in one multi-variate model in 
patients who were given etomidate
Warner KJ, Cuschieri J, 
Jurkovich GJ, et al. 
2009
Post-hoc analysis of clinical 
trial of prehospital hypertonic 
saline administration
Critically ill trauma patients requiring 
intubation
94
Not specified 
(etomidate not 
randomized)
Development of posttraumatic 
ARDS
Higher rates of late onset ARDS in 
patients given etomidate
CST, corticotropin stimulation test; ICU, intensive care unit; PICU, pediatric intensive care unit; SOFA, sequential organ failure assessment; ARDS, acute respiratory distress syndrome
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